Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/222831
Title: | Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study |
Author: | Bento, Leyre Gutiérrez, Antonio Martínez, Carmen Consejo Ortí Verdet, María Sorribes, Marina Carolina Caballero, Ana Peña, Marta Pérez, Ariadna Jiménez-ubieto, Ana Medina, Lucía Bastos-oreiro, Mariana Fernández Caldas-gonzález, Paula Navarro, Belén Salcedo, Isabel Abrisqueta, Pau Español, Ignacio Cornago, Javier Martín-moro, Fernando García, Lucía Gómez, Pilar Rosario Varela, María Puente, María Zanabili, Joud Zudaire, Teresa Zeberio, Izaskun Del Campo, Raquel González, Leslie González, Pedro Blázquez, Cristina Rovira, Jordina Sitges, Marta Franch-sarto, Mireia Cabero, Almudena Mussetti, Alberto Montoro, Juan Sampol, Antonia Sureda, Anna Caballero, Dolores Martín García-sancho, Alejandro |
Issue Date: | 31-Mar-2025 |
Publisher: | American Society of Hematology |
Abstract: | We performed a retrospective multicenter study including 791 patients with relapsed/ refractory (R/R) large B-cell lymphoma (LBCL) who underwent autologous stem cell transplantation (ASCT). After a median follow-up of 74 months from infusion, 65% were alive and 84% free of disease. Progression-free survival (PFS) and overall survival (OS) at 6 years were 51% and 63%, respectively. Non-relapse mortality at 1 year was 9%. Age >60 years at ASCT (hazard ratio [HR], 1.31; 95% CI, 1.06-1.62; P = .011), ASCT as >= 3rd line (HR, 1.81; 95% CI, 1.42-2.31; P < .001), and partial response (PR) vs complete response (CR) at ASCT (HR, 1.46; 95% CI. 1.18-1.81; P < .001) were independent variables influencing PFS. Age >60 years at ASCT (HR, 1.62; 95% CI, 1.24-2.12; P < .001), time period before 1 November 2012 (HR, 1.40; 95% CI, 1.07-1.83; P = .014), ASCT as >= 3rd line (HR, 1.77; 95% CI, 1.32-2.37; P < .001), PR vs CR (HR, 1.58; 95% CI, 1.22-2.05; P < .001), and stable disease vs CR pre-ASCT (HR, 3.41; 95% CI, 1.81-6.45; P < .001) were variables associated with worse OS. Refractory/early relapse did not significantly influence survival (6-year PFS and OS in patients with refractory, early, and late relapse were 54% and 64%, 46% and 62%, and 49% and 63%, respectively). To our knowledge, this is the largest series analyzing the efficacy of ASCT in patients with R/R LBCL after rituximab-containing frontline therapy. Our results indicate that ASCT is a curative option for patients with chemosensitive disease. |
Note: | Reproducció del document publicat a: https://doi.org/10.1182/bloodadvances.2024015415 |
It is part of: | Blood Advances, 2025, vol. 9, issue. 13, p. 3281-3292 |
URI: | https://hdl.handle.net/2445/222831 |
Related resource: | https://doi.org/10.1182/bloodadvances.2024015415 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
main (9).pdf | 1.49 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.